Peptic Ulcer Clinical Trial
Official title:
A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease
Although all PPIs are effective, there are some differences in their clinical performance, particularly in terms of the degree and speed of gastric acid suppression. Few data are also available about their effect of the pathophysiological mechanisms of gastritis and peptic ulcer disease. Aim of the present study is to investigate the effect of therapy with esomeprazole or rabeprazole on the mechanism of pathogenesis of gastritis and particularly on the pattern of release of pro- and anti- inflammatory cytokines associated to peptic ulcerative process by the gastric mucosa.
Although all PPIs are effective, there are some differences in their clinical performance,
particularly in terms of the degree and speed of gastric acid suppression. Few data are also
available about their effect of the pathophysiological mechanisms of gastritis and peptic
ulcer disease.
Triggering receptor expressed on myeloid cells (TREM)-1 is a recently discovered receptor
expressed on the surface of neutrophils and monocytes. Engagement of TREM-1 has been
reported to trigger the synthesis of proinflammatory cytokines. A soluble form of TREM-1,
named sTREM-1, was observed and identified at significant levels in serum samples from
patients with disease of the gastrointestinal tract inflammatory bowel disease. rendering
interest about the implication of sTREM-1 in their pathogenesis.
sTREM-1 was also found elevated in the gastric juice of patients with peptic ulcer disease
being correlated to the degree of the infiltration of the gastric mucosa by neutrophils.
Published data of our group elicit that sTREM-1 secretion is a crucial parameter for
evolution from chronic gastritis to peptic ulcer disease. Samples of biopsies of gastric
mucosa were cultured in the absence/presence of endotoxins showing that the inflamed mucosa
was a potent secretor of sTREM-1 whatever ceased to exist post-antisecretory treatment.
Aim of the present study is to investigate the effect of therapy with esomeprazole or
rabeprazole on the mechanism of pathogenesis of gastritis and particularly on the pattern of
release of pro- and anti- inflammatory cytokines associated to peptic ulcerative process by
the gastric mucosa.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00471029 -
Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
|
Phase 4 | |
Completed |
NCT00152399 -
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
|
Phase 2 | |
Not yet recruiting |
NCT02961296 -
Helicobacter Pylori Antibiotic Susceptibility Testing of Korea
|
N/A | |
Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
Completed |
NCT02342470 -
Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users
|
Phase 2 | |
Completed |
NCT02296021 -
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT00977678 -
Drop in Gastroscopy - Experience After 9 Months
|
N/A | |
Terminated |
NCT04025983 -
Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection
|
N/A | |
Recruiting |
NCT03868267 -
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
|
||
Completed |
NCT05237115 -
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT01667718 -
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
|
Phase 4 | |
Not yet recruiting |
NCT04784910 -
Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
|
Phase 3 | |
Recruiting |
NCT02436018 -
WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy
|
N/A | |
Completed |
NCT03367897 -
Bleeding Ulcer and Erosions Study "BLUE Study"
|
||
Active, not recruiting |
NCT02001727 -
HEP-FYN 12-Years Follow-up
|
N/A | |
Completed |
NCT01376414 -
H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department
|
N/A | |
Completed |
NCT01667692 -
Aizthromycin or Clarithromycin in H-pylori Eradication Regimen
|
Phase 4 | |
Completed |
NCT01080326 -
Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
|
N/A | |
Completed |
NCT02536989 -
Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot
|
Phase 4 | |
Completed |
NCT00920400 -
Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract
|
N/A |